$Prospective Study of Estramustine Phosphate for Hormone Refractory Prostate Cancer Patients following Androgen Deprivation Therapy$

Prospective Study of Estramustine Phosphate for Hormone Refractory Prostate Cancer Patients following Androgen Deprivation Therapy

Introduction: Estramustine phosphate (EMP) in combination with other cytotoxic agents has been widely used in clinical trials as an anti-tumor agent for the treatment of hormone-refractory prostate cancer (HRPC). However, few prospective studies have considered the efficacy of EMP monotherapy for HR...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Urologia internationalis 2005-01, Vol.75 (1), p.43-49
Hauptverfasser:	Hirano, Daisaku, Minei, Sadatsugu, Kishimoto, Yuichi, Yamaguchi, Kenya, Hachiya, Takahiko, Yoshida, Toshio, Yoshikawa, Tetsuo, Endoh, Makoto, Yamanaka, Yataroh, Yamamoto, Tadao, Satoh, Yasuo, Ishida, Hajime, Okada, Kiyoki, Takimoto, Yukie
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - blood Adenocarcinoma - drug therapy Adenocarcinoma - pathology Aged Aged, 80 and over Androgens - therapeutic use Antineoplastic Agents, Hormonal - therapeutic use Biomarkers, Tumor - blood Disease Progression Estramustine - therapeutic use Follow-Up Studies Humans Male Middle Aged Neoplasm Staging Original Paper Prospective Studies Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!